Strain Data Sheet

RBRC01678

Strain Information

Image
BRC No.RBRC01678
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameFVB.129P2-Nf2<tm1Gth>/GthRbrc
Former Common nameNF2KO3
H-2 Haplotype
ES Cell line
Background strainFVB/NJcl
Appearance
Strain developmentDeveloped by Drs. Marco Giovannini and Gilles Thomas, INSERM in 2000. A Ires-lacZ-hygromtcin resistance cassette was inserted into exon 3 of Nf2 gene. The mutant mice were backcrossed to FVB/N for 18 times.
Strain descriptionNf2 isoform 1 knock-out mice. Nf2, Neurofiboromatosis type 2 is a tumor suppressor gene encoding a putative cytoskeletal asssociated protein. Homozygous mutant mice die prior to E9.5. 44% of heterozygotes develop osteoblastic hyperplasia. 38% of heterozygotes exhibit renal tubular cell hyperplasia. 6% of heterozygotes exhibit odontoblastic hyperplasia.
Colony maintenance
References
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.
Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff J M, Berns A, Thomas G
Genes Dev., 14, 1617-1630 (2000). 10887156

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
HBB2rabbit bata-globin polyA11HBB2
  • familial meningioma(MedGEN)

  • meningioma(DisGeNET)

  • neurofibromatosis type 2(DisGeNET, MedGEN)
    • more 1 Diseases
  • schwannomatosis 1(MedGEN)
    • IRESinternal ribosomal entry site (EMCV)11
  • familial meningioma(MedGEN)

  • meningioma(DisGeNET)

  • neurofibromatosis type 2(DisGeNET, MedGEN)
    • more 1 Diseases
  • schwannomatosis 1(MedGEN)
    • Nf2neurofibromin 211Nf2targeted mutation 1, Gilles Thomas
  • familial meningioma(MedGEN)

  • meningioma(DisGeNET)

  • neurofibromatosis type 2(DisGeNET, MedGEN)
    • more 1 Diseases
  • schwannomatosis 1(MedGEN)
    • hyghygromycin phasphotransferase (E. coli)11hyg
  • familial meningioma(MedGEN)

  • meningioma(DisGeNET)

  • neurofibromatosis type 2(DisGeNET, MedGEN)
    • more 1 Diseases
  • schwannomatosis 1(MedGEN)
    • lacZbeta-galactosidase (E. coli)11
  • familial meningioma(MedGEN)

  • meningioma(DisGeNET)

  • neurofibromatosis type 2(DisGeNET, MedGEN)
    • more 1 Diseases
  • schwannomatosis 1(MedGEN)

    • Phenotype

    Annotation by Mammalian phenotyhpe ontology
  • abnormal Schwann cell morphology(MP:0001106)

  • abnormal osteoblast morphology(MP:0004986)

  • abnormal renal tubule morphology(MP:0002703)

  • abnormal tooth development(MP:0000116)

  • decreased body size(MP:0001265)
    • more 24 phenotypes
  • decreased body weight(MP:0001262)

  • decreased survivor rate(MP:0008770)

  • delayed tooth eruption(MP:0003053)

  • embryonic lethality, complete penetrance(MP:0011092)

  • failure of tooth eruption(MP:0000121)

  • increased Schwannoma incidence(MP:0010310)

  • increased fibroadenoma incidence(MP:0010364)

  • increased hamartoma incidence(MP:0010306)

  • increased lung adenocarcinoma incidence(MP:0002027)

  • increased mesothelioma incidence(MP:0010309)

  • increased neurofibroma incidence(MP:0010314)

  • increased neurofibrosarcoma incidence(MP:0002030)

  • increased odontoma incidence(MP:0010353)

  • increased odontosarcoma incidence(MP:0010354)

  • increased osteoma incidence(MP:0010313)

  • increased osteosarcoma incidence(MP:0003789)

  • increased renal carcinoma incidence(MP:0010384)

  • increased sarcoma incidence(MP:0002032)

  • increased susceptibility to otitis media(MP:0001850)

  • neoplasm(MP:0002006)

  • nervous system phenotype(MP:0003631)

  • osseous metaplasia(MP:0010347)

  • postnatal lethality, complete penetrance(MP:0011085)

  • premature death(MP:0002083)
    • Detailed phenotype data

    Ordering Information

    Donor DNAEncephalomyocarditis virus (EMCV) internal ribosomal entry site (ires), E. coli lacZ, mouse Pgk promoter, E. coli Hyg, rabbit bata globin poly A
    Research applicationFluorescent Proteins/lacZ System
    Neurobiology Research
    Specific Term and ConditionsThe RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Genes & Development., 14, 1617-1630 (2000).In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.
    RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.
    In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters.
    DepositorMarco Giovannini (INSERM)
    Strain Statusan icon for Frozen embryosFrozen embryos
    Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
    Cryopreserved embryos (within 1 month)
    Additional Info.Necessary documents for ordering:
    1. Approval form (Japanese / English)
    2. Order form (Japanese / English)
    3. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    4. Acceptance of responsibility for living modified organism (Japanese / English)

    Genotyping protocol -PCR-

    BRC mice in Publications

    Nakata H, Hashimoto T, Seki Y, Mekada K, Obata Y, Yoshiki A.
    Simultaneous detection of multiple transgenes for genetically-modified mouse strains.
    Exp Anim 58(4) 437-42(2009) 19654444